Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
8.8000
-0.0500 (-0.56%)
NASDAQ · Last Trade: Nov 14th, 6:27 PM EST
Detailed Quote
Previous Close
8.850
Open
8.770
Bid
8.850
Ask
9.700
Day's Range
8.560 - 9.050
52 Week Range
5.635 - 15.92
Volume
3,549,469
Market Cap
647.44M
PE Ratio (TTM)
-5.789
EPS (TTM)
-1.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,542,088
Chart
About Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
Day One Biopharmaceuticals Inc is a biotechnology company focused on developing innovative therapies for patients with serious diseases, particularly in the field of oncology. The company is dedicated to creating targeted treatments for pediatric and adult patients, with an emphasis on precision medicine that addresses the specific genetic and molecular characteristics of their cancers. By leveraging advanced science and a deep understanding of cancer biology, Day One aims to deliver effective, safe, and impactful therapeutic options, improving the lives of patients facing difficult-to-treat conditions. Read More
Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2025.
Day One Biopharmaceuticals reports Q2 2025 earnings with revenue growth but wider-than-expected loss, causing an 11.8% stock drop. OJEMDA sales rise 10% QoQ, while pipeline advances.
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025.
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025.
